Gilmore Lab Publications
|1. Radke K, T Gilmore & GS Martin. 1980. Phosphorylation of a 36,000 molecular weight cellular polypeptide in Rous sarcoma virus-transformed fibroblasts. In, Protein Phosphorylation and Bio-Regulation (eds. G Thomas, E Podesta, and J Gordon), S Karger, Basel, Switzerland, pp 186-192.
2.Radke K, T Gilmore & GS Martin. 1980. Transformation by Rous sarcoma virus: a cellular substrate for transformation-specific phosphorylation contains phosphotyrosine. Cell 21 :821-828. (Abstract Link)
3.Pawson T, J Guyden, T-H Kung, K Radke, T Gilmore & GS Martin. 1980. A strain of Fujinami sarcoma virus which is temperature-sensitive in protein phosphorylation and cellular transformation. Cell 22: 767-775. (Abstract Link)
4.Gilmore T, K Radke & GS Martin. 1982. Tyrosine phosphorylation of a 50K cellular polypeptide associated with the Rous sarcoma virus transforming protein, pp60src. Molecular and Cellular Biology 2: 199-206. (Abstract Link)
5.Gilmore T & GS Martin. 1983. Phorbol ester and diacylglycerol induce protein phosphorylation at tyrosine. Nature 306: 487-490. (Abstract Link)
6.Martin GS, K Radke, C Carter, P Moss, P Dehazya & T Gilmore. 1984. The role of protein phosphorylation at tyrosine in transformation and mitogenesis. Cold Spring Harbor Conference on Cell Proliferation and Cancer. Journal of Cell Physiology Supplement 3: 139-149. (Abstract Link)
7.Moss P, K Radke, V Carter, J Young, T Gilmore & GS Martin. 1984. Cellular localization of the transforming protein of wild-type and temperature-sensitive Fujinami sarcoma virus. Journal of Virology 52: 557-565. (Abstract Link)
8.Gilmore T, J DeClue & GS Martin. 1985. Tyrosine kinase activity associated with the v-erbB gene product. In, The Cancer Cell (eds. G Ferramisco, B Ozanne, and C Stiles) Volume 3: 25-32.
9.Gilmore TD, J DeClue & GS Martin. 1985. Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro. Cell 40: 609-618. (Abstract Link)
10.Gilmore TD & HM Temin. 1986. Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell 44: 791-800. (Abstract Link)
11.Luk K-C, T Gilmore & A Panganiban. 1987. The spleen necrosis virus int gene product expressed in Escherichia coli has DNA binding activity and mediates att and U5-specific multimer formation in vitro. Virology 57: 127-136. (Abstract Link)
12.Gilmore TD & HM Temin. 1988. v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells. Journal of Virology 62: 703-714. (Abstract Link)
13.Capobianco A, DL Simmons & TD Gilmore. 1990. Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene 5: 257-266. (Abstract Link)
14.Delwart EL, G Mosialos & T Gilmore. 1990. Retroviral envelope glycoproteins contain a “leucine zipper”-like repeat. AIDS Research and Human Retroviruses 6: 703-706. (Abstract Link)
15.Kamens J, P Richardson, G Mosialos, R Brent & TD Gilmore. 1990. Oncogenic transformation by vRel requires an amino-terminal activation domain. Molecular and Cellular Biology 10: 2840-2847. (Abstract Link)
16.Gilmore TD. 1990. NF-kB, KBF1, dorsal, and related matters. Cell 62: 841-843. (Abstract Link)
17.Dailey D, GL Schieven, MY Lim, T Gilmore, J Thorner & GS Martin. 1990. Novel yeast protein kinase (YPK1 gene product) is a 40-kilodalton phosphotyrosyl protein associated with protein-tyrosine kinase activity. Molecular and Cellular Biology 10: 6244-6256. (Abstract Link)
18.Richardson PM & TD Gilmore. 1991. vRel is an inactive member of the Rel family of transcriptional activating proteins. Journal of Virology 65: 3122-3130. (Abstract Link)
19.Gilmore TD. 1991. Malignant transformation by mutant Rel proteins. Trends in Genetics 7: 318-322. (Abstract Link)
20.Mosialos G, P Hamer, AJ Capobianco, R Laursen & TD Gilmore. 1991. A protein kinase A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Molecular and Cellular Biology 11: 5867-5877. (Abstract Link)
21.Capobianco A & TD Gilmore. 1991. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kB binding site. Oncogene 6: 2203-2210. (Abstract Link)
22.Morin P & TD Gilmore. 1992. The C terminus of the NF-kB p50 precursor protein and an IkB isoform contain transcription activation domains. Nucleic Acids Research 20: 2453-2458. (Abstract Link)
23.Capobianco AJ, D Chang, G Mosialos & TD Gilmore. 1992. p105, the NF-kB p50 precursor, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken cells. Journal of Virology 66: 3758-3767. (Abstract Link)
24.Gilmore TD. 1992. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surveys 15: 69-87. (Abstract Link)
25.Morin PJ, G Subramanian & TD Gilmore. 1992. AAT1, a gene encoding a mitochondrial aspartate aminotransferase in Saccharomyces cerevisiae. Biochimica et Biophysica Acta 1171: 211-214. (Abstract Link)
26.Mosialos G & TD Gilmore. 1993. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene 8 :721-730. (Abstract Link)
27.Capobianco AJ & TD Gilmore. 1993. A conditional mutant of vRel containing sequences from the human estrogen receptor. Virology 193:1 60-170. (Abstract Link)
28.Morin PJ, GS Subramanian & TD Gilmore. 1993. GAL4-IkBa and GAL4-IkBg activate transcription by different mechanisms. Nucleic Acids Research 21: 2157-2163. (Abstract Link)
29.Sarkar S & TD Gilmore. 1993. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene 8: 2245-2252. (Abstract Link)
30.Sif S, AJ Capobianco & TD Gilmore. 1993. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts. Oncogene 8: 2501-2509. (Abstract Link)
31.White DW & TD Gilmore. 1993. Temperature-sensitive transforming mutants of the v-rel oncogene. Journal of Virology 67: 6876-6881. (Abstract Link)
32.Sif S & TD Gilmore. 1993. NF-kB p100 is one of the high-molecular-weight proteins associated with the v-Rel oncoprotein in transformed chicken spleen cells. Journal of Virology 67: 7612-7617. (Abstract Link)
33.Gilmore TD & PJ Morin. 1993. The IkB proteins: members of a multifunctional family. Trends in Genetics 9: 427-433. (Abstract Link)
34.Feinstein R, WK Bolton, JN Quinones, G Mosialos, S Sif, JL Huff, AJ Capobianco & TD Gilmore. 1994. Characterization of a chicken cDNA encoding the retinoblastoma gene product. Biochimica et Biophysica Acta 1218: 82-86. (Abstract Link)
35.Sif S & TD Gilmore. 1994. Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. Journal of Virology 68: 7131-7138. (Abstract Link)36.White DW, A Roy & TD Gilmore. 1995. The v-Rel oncoprotein blocks apoptosis and proteolysis of IkB-a in transformed chicken spleen cells. Oncogene 10: 857-868. (Abstract Link)37.Gilmore TD, DW White, S Sarkar & S Sif. 1995. Malignant transformation of cells by the v-Rel oncoprotein. In, The DNA Provirus: Howard Temin’s Scientific Legacy (eds. GM Cooper, R Greenberg Temin, and B Sugden), American Society for Microbiology, Washington D.C., pp 109-128.
38.Morin PJ, J Downs, AM Snodgrass & TD Gilmore. 1995. Genetic analysis of growth inhibition by GAL4-IkB-a in Saccharomyces cerevisiae. Cell Growth & Differentiation 6: 789-798. (Abstract Link)
39.Gilmore TD. 1995. Regulation of Rel transcription complexes. In, Frontiers in Molecular Biology: Eukaryotic Gene Transcription (ed. S Goodbourn), Oxford University Press, Oxford, England, pp 102-131.
40.White DW, GA Pitoc & TD Gilmore. 1996. Interaction of the v-Rel oncoprotein with NF-kB and IkB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-kB p52 are functional in vitro and in vivo. Molecular and Cellular Biology 16: 1169-1178. (Abstract Link)
41.White DW & TD Gilmore. 1996. Bcl-2 and CrmA have different effects on transformation, apoptosis, and the stability of IkB-a in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins. Oncogene 13: 891-899. (Abstract Link)
42.Gilmore TD, M Koedood, KA Piffat & DW White. 1996. Rel/NF-kB/IkB proteins and cancer. Oncogene 13:1367-1378. (Abstract Link)
43.Gilmore TD (editor). 1997. Rel/NF-kB. Seminars in Cancer Biology, Academic Press, Cambridge, England. Volume 8-2, pp 61-129.
44.Barkett M, D Xue, HR Horvitz & TD Gilmore. 1997. Phosphorylation of IkB-a inhibits its cleavage by caspase CPP32 in vitro. Journal of Biological Chemistry 272: 29419-29422. (Abstract Link)
45.Gilmore TD. 1997. Clinically relevant findings. Journal of Clinical Investigation 100: 2935-2936. (Abstract Link)
46.Sylla B, SC Hung, DM Davidson, E Hatzivassiliou, NL Malinin, D Wallach, TD Gilmore, E Kieff & G Mosialos. 1998. Epstein-Barr virus transforming protein latent infection membrane protein 1 activates transcription factor NF-kB through a pathway that includes the NF-kB-inducing kinase and the IkB kinases IKKa and IKKb. Proceedings of the National Academy of Sciences USA 95: 10106-10111. (Abstract Link)
47.Wang Y, JE Dooher, M Koedood Zhao & TD Gilmore. 1999. Characterization of mouse Trip6: a putative intracellular signaling protein. Gene 234: 403-409. (Abstract Link)
48.Epinat J-C & Gilmore TD. 1999. In vitro-translated diphtheria toxin A chain inhibits translation in wheat germ extracts: analysis of biologically active, caspase-3-resistant diphtheria toxin mutants. Biochimica et Biophysica Acta 1472: 34-41. (Abstract Link)
49.Gilmore TD, J-C Epinat & M Barkett. 1999. Misregulation of a signal transduction pathway: role of Rel/NF-kB transcription factors in oncogenesis. In, DNA Alterations in Cancer: Genetic and Epigenetic Changes (ed. M Ehrlich), BioTechniques Books, Eaton Publishing, Natick, MA, USA. pp 121-136.
50. Koedood Zhao M, Y Wang, K Murphy, J Yi, MC Beckerle & TD Gilmore. 1999. LIM domain-containing protein Trip6 can act as a co-activator for the v-Rel transcription factor. Gene Expression 8: 207-217. (Abstract Link)
51. Gilmore TD. 1999. The Rel/NF-kB signal transduction pathway: introduction. Oncogene 18: 6842-6844. (Abstract Link)
52. Epinat J-C & TD Gilmore. 1999. A variety of agents can act at multiple levels to inhibit the Rel/NF-kB signal transduction pathway. Oncogene 18: 6896-6909. (Abstract Link)
53. Barkett M & TD Gilmore. 1999. Control of apoptosis by Rel/NF-kB transcription factors. Oncogene 18: 6910-6924. (Abstract Link)
54. Gilmore TD. 1999. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18: 6925-6937. (Abstract Link)
55. Epinat J-C, D Kazandjian, DD Harkness, S Petros, J Dave, DW White & TD Gilmore. 2000. Mutant Envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein. Oncogene 19: 599-607. (Abstract Link) (Data-link)
56. Epinat J-C, EL Dvorin & TD Gilmore. 2000. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient transformation of chicken spleen cells. Oncogene 19: 3131-3137. (Abstract Link) (Data-link 1)
57. Barkett M, JE Dooher, L Lemonnier, L Simmons, JN Scarpati, Y Wang & TD Gilmore. 2001. Three mutations in the retroviral oncoprotein v-Rel render it resistant to cleavage by caspase-3. Biochimica et Biophysica Acta 1526: 25-36. (Abstract Link) (Data-link 2)
58. Wang Y & TD Gilmore. 2001. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochimica et Biophysica Acta 1538: 260-272. (Abstract Link)
59. Piffat KA, R Hrdlickova, J Nehyba, T Ikeda, A Liss, S Huang, S Sif, TD Gilmore & HR Bose Jr. 2001. The chicken RelB transcription factor has transactivation sequences and a tissue-specific expression pattern that are distinct from mammalian RelB. Molecular Cell Biology Research Communications 4: 266-275. (Abstract Link) (Data-link 3)
60. Gilmore TD, C Cormier, J Jean-Jacques & M-E Gapuzan. 2001. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 20: 7098-7103. (Abstract Link) (Data-link 4)
61.Li C, EA Pace, M-C Liang, E Lobkovsky, TD Gilmore & JA Porco Jr. 2001. Total synthesis of the NF-kB inhibitor (-)-cycloepoxydon: utilization of tartrate-mediated nucleophilic epoxidation. Journal of the American Chemical Society 123: 11308-11309. (Abstract Link)
62.Gilmore TD, M-E Gapuzan, D Kalaitzidis & D Starczynowski. 2002. Rel/NF-kB/IkB signal transduction in the generation and treatment of human cancer. Cancer Letters 181 :1-9. (Abstract Link)
63. Kalaitzidis D & TD Gilmore. 2002. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes, Chromosomes & Cancer 34: 129-135. (Abstract Link)
64.Gapuzan M-E, P Yufit & TD Gilmore. 2002. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kB have a malignantly transformed phenotype. Oncogene 24: 2484-2492. (Abstract Link) (Image Link)
65. Li C, S Bardhan, EA Pace, M-C Liang, TD Gilmore & JA Porco Jr. 2002. The angiogenesis inhibitor epoxyquinol A: total synthesis and inhibition of transcription factor NF-kB. Organic Letters 4: 3267-3270. (Abstract Link)
66. Kalaitzidis D, RE Davis, A Rosenwald, LM Staudt & TD Gilmore. 2002. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kB signal transduction pathway. Oncogene 21: 8759-8768. (Abstract Link)
67. Gilmore TD. 2003. Rel/NF-kB/IkB signal transduction and cancer. In, Signal Transduction in Cancer (ed. DA Frank), pp 241-265. (Abstract Link)
68. Wang Y & TD Gilmore. 2003. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochimica et Biophysica Acta 1593: 115-120. (Abstract Link) (Data-link 5 — Link to full Table 1)
69. Gilmore TD & G Mosialos. 2003. Viruses as intruders in the Rel/NF-kB signaling pathway. In, Nuclear Factor-kB: Regulation and Role in Disease (ed. R Beyaert), Kluwer Academic Publishers, The Netherlands, pp 91-115.
70. Liang M-C, S Bardhan, C Li, EA Pace, JA Porco Jr & TD Gilmore. 2003. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of Nuclear Factor kB by inhibiting Inhibitor of kB kinase. Molecular Pharmacology 64: 123-131. (Abstract Link)
71. Gapuzan M-ER, GA Pitoc & TD Gilmore. 2003. Mutations within a conserved protein kinase A recognition sequence confer temperature-sensitive and partially defective activities onto mouse c-Rel. Biochemical and Biophysical Research Communications 307: 92-99. (Abstract Link)
72. Starczynowski D, JG Reynolds & TD Gilmore. 2003. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 22: 6928-6936. (Abstract Link) (Data-link 6)
73. Gilmore TD, J Jean-Jacques, R Richards, C Cormier, J Kim & D Kalaitzidis. 2003. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology 316: 9-16. (Abstract Link)
74. Gilmore TD, D Kalaitzidis, M-C Liang & DT Starczynowski. 2004. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23: 2275-2286. (Abstract Link)
75. Kalaitzidis D, J Ok, L Sulak II, D Starczynowski & TD Gilmore. 2004. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene 23: 7580-7587. (Abstract Link) (Data Link 7)
76. Kalaitzidis D & TD Gilmore. 2005. Transcription factor cross-talk: Estrogen receptor and NF-kB. Trends in Endocrinology and Metabolism 16: 46-52. (Abstract Link) (featured cover photo)
77. Gapuzan M-ER, O Schmah, AD Pollock, A Hoffmann & TD Gilmore. 2005. Immortalized embryonic fibroblasts from NF-kB RelA knockout mice show phenotypic heterogeneity and maintain sensitivity to tumor necrosis factor alpha after transformation by v-Ras. Oncogene 24: 6574-6583. (Abstract Link)
78. Starczynowski DT, JG Reynolds & TD Gilmore. 2005. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL can enhance its in vitro transforming ability. Oncogene 24: 7355-7368. (Abstract Link) (Data Link 8)
79. Liang M-C, S Bardhan, EA Pace, D Rosman, JA Beutler, JA Porco Jr & TD Gilmore. 2006. Inhibition of transcription factor NF-kB signaling proteins IKKb and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochemical Pharmacology 71: 634-645. (Abstract Link)
80. Liang M-C, S Bardhan, JA Porco Jr & TD Gilmore. 2006. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkBa-deficient diffuse large B-cell lymphoma cell line. Cancer Letters 241: 69-78. (Abstract Link)
81. Perkins ND & TD Gilmore. 2006. Good cop, bad cop: the different faces of NF-kB. Cell Death & Differentiation 13: 759-772. (Abstract Link)
82. Gilmore TD. 2006. Introduction to NF-kB: players, pathways, perspectives. Oncogene 25: 6680-6684. (Abstract Link)
83. Courtois G & TD Gilmore. 2006. Mutations in the NF-kB signaling pathway: implications for human disease. Oncogene 25: 6831-6843. (Abstract Link)
84. Gilmore TD & M Herscovitch. 2006. Inhibitors of NF-kB signaling: 785 and counting. Oncogene 25: 6887-6899. (Abstract Link)
85. Sullivan JC, D Kalaitzidis, TD Gilmore & JR Finnerty. 2007. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis. Development Genes and Evolution 217: 63-72. (Abstract Link)
86. Starczynowski DT, H Trautmann, C Pott, L Harder, N Arnold, JA Africa, JR Leeman, R Siebert & TD Gilmore. 2007. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL’s in vitro transforming activity. Oncogene 26: 2685-2694. (Abstract Link) (Data Link 9)
87. Gilmore TD. 2007. Multiple myeloma: lusting for NF-kB. Cancer Cell 12: 95-97. (Abstract Link)
88. Herscovitch M, W Comb, T Ennis, K Coleman, S Yong, B Armstead, D Kalaitzidis, S Chandani & TD Gilmore. 2008. Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347. Biochemical and Biophysical Research Communications 367: 103-108. (Abstract Link) (Data Link 10)
89. Leeman JR, MA Weniger, TF Barth & TD Gilmore. 2008. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL. Oncogene 27: 6770-6781 (Abstract Link) (Data Link 11)
90. Leeman JR & TD Gilmore. 2008. Alternative splicing in the NF-kB signaling pathway. Gene 423: 97-107. (Abstract Link)
91. Garbati MR & TD Gilmore. 2008. Ser484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivation. Gene Expression 14: 195-205. (Abstract Link) (Data Link 12)
92. Gilmore TD, ND Perkins & G Franzoso. 2009. Getting away from it all in Capri: The 2008 EMBO Workshop on NF-kB. Cell Death & Differentiation 16: 651-654. (Abstract Link)
93. Chin M*, M Herscovitch*, N Zhang, DJ Waxman & TD Gilmore. 2009. Overexpression of an activated version of the REL oncoprotein enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 28: 2100-2111. *co-first authors (Abstract Link)
94. Sullivan JC, FS Wolenski, AM Reitzel, CE French, N Traylor-Knowles, TD Gilmore & JR Finnerty. 2009. Two alleles of NF-kB in the sea anemone Nematostella vectensis are widely dispersed in nature and encode proteins with distinct activities. PLoS ONE 4: e7311. doi:10.137/journal.pone.0007311 (Paper Link) (Abstract Link)
95. Garbati MR, G Alco & TD Gilmore. 2010. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Letters 291: 237-245. (Abstract Link) (Data Link 13)
96. Gilmore TD, RC Thompson & AC Faber. 2010. Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. Cell Cycle 9: 448-449. (Abstract Link)
97. Thompson RC*, M Herscovitch*, I Zhao, TJ Ford & TD Gilmore. 2011. NF-kB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. Journal of Biological Chemistry 286: 1675-1681. (Abstract Link) *co-first authors
98. Garbati M, RC Thompson, L Haery & TD Gilmore. 2011. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Letters 302: 76-83. (Abstract Link) (Data Link 14). Published Erratum, in Cancer Letters (2012) 315: 96.
99. Wolenski F, MR Garbati, TJ Lubinski, N Traylor-Knowles, DJ Stefanik, E Dresselhaus, H Goucher, JR Finnerty & TD Gilmore. 2011. Characterization of the core elements of the NF-kB signaling pathway of the sea anemone Nematostella vectensis. Molecular and Cellular Biology 31: 1076-1087. (Abstract Link) (featured cover photo)
100. Gilmore TD & MR Garbati. 2011. Inhibition of NF-kB signaling as a strategy in disease therapy. Current Topics in Microbiology and Immunology 349: 245-263. (Abstract Link)
101. Gilmore TD & S Gerondakis. 2011. The c-Rel transcription factor in development and disease. Genes & Cancer 7: 695-711. (Abstract Link)
102. Wolenski FS, S Chandani, DJ Stefanik, N Jiang, E Chu, JR Finnerty & TD Gilmore. 2011. Two polymorphic residues account for the differences in DNA binding and transcriptional activation by NF-kB proteins encoded by naturally occurring alleles in Nematostella vectensis. Journal of Molecular Evolution 73: 325-336. (Abstract Link)
103. Yeo AT, JA Porco Jr & TD Gilmore. 2012. Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis. Cancer Letters 318: 53-60. (Abstract Link)
104. Gilmore TD & FS Wolenski. 2012. Evolution of NF-kB: where did it come from and why? Immunological Reviews 246: 14-35. (Abstract Link)
105. Wolenski F, J Finnerty & T Gilmore. 2012. Preparation of antiserum and detection of proteins by Western blotting using the starlet sea anemone, Nematostella vectensis. Protocol Exchange: doi:10.1038/protex.2012.057
106. Wolenski FS, CA Bradham, JR Finnerty & TD Gilmore. 2013. NF-kB is required for cnidocyte development in the sea anemone Nematostella vectensis. Developmental Biology 373: 205-215. (Abstract Link)
107. Stefanik DJ, FS Wolenski, TD Gilmore & JR Finnerty. 2013. Isolation of DNA, RNA and protein from the starlet sea anemone Nematostella vectensis. Nature Protocols 8: 892-899. (Abstract Link)
108. Layden MJ, E Rottinger, FS Wolenski, TD Gilmore & MQ Martindale. 2013. Microinjection techniques for reverse genetic analysis in the starlet sea anemone, Nematostella vectensis. Nature Protocols 8: 924-934. (Abstract Link)
109. Wolenski FS, MJ Layden MQ Martindale, TD Gilmore & JR Finnerty. 2013. Characterizing the spatiotemporal expression of RNAs and proteins in the starlet sea anemone, Nematostella vectensis. Nature Protocols 8: 900-915. (Abstract Link)
110. Gilmore TD, AM Tarrant & JR Finnerty. 2013. A report from the second Nematostella vectensis research conference. Development Genes and Evolution 223: 207-211. (Abstract Link)
111. Thompson RC, I Vardinogiannis & TD Gilmore. 2013. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS ONE 8: e62822 (Abstract Link)
112. Thompson RC, I Vardinogiannis & TD Gilmore. 2013. Identification of an NF-κB p50-p65-responsive site in the human MIR155HG promoter. BMC Molecular Biology 14: 24 (Abstract Link)
113. Cote SM, TD Gilmore*, R Shaffer, U Weber, R Bollam, MS Golden, K Glover, M Herscovitch, T Ennis, KN Allen & A Whitty*. 2013. Mutation of nonessential cysteines shows that the NF-κB essential modulator (NEMO) forms a constitutive noncovalent dimer that binds IκB kinase-β (IKKβ) with high affinity. Biochemistry 52: 9141-9154 (Abstract Link) (Data Link) *Co-corresponding authors
114. Haery L, JG Lugo-Picó, RA Henry, AJ Andrews & TD Gilmore. 2014. Histone acetyltransferase-deficient p300 mutants in diffuse large B-cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth. Molecular Cancer 13: 29. (Abstract Link) (Data Link)
115. Zhou L, A Yeo, C Ballarano, U Weber, KN Allen*, TD Gilmore* & A Whitty*. 2014. Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO). Biochemistry 53: 7929-7944. *Co-corresponding authors (Abstract Link)
116. Tarrant AM, TD Gilmore, AM Reitzel, O Levy, U Technau & MQ Martindale. 2015. Current directions and future perspectives from the third Nematostella research conference. Zoology 118: 135-140. (Abstract Link)
117. Gilmore TD & C Gelinas. 2015. Methods for assessing the in vitro transforming activity of NF-κB transcription factor c-Rel and related proteins. Methods in Molecular Biology 1280: 427-446. (Abstract Link)
118. Siggers T, TD Gilmore, B Barron & A Penvose. 2015. Characterizing the DNA binding site specificity of NF-κB with protein binding microarrays (PBMs). Methods in Molecular Biology 1280: 609-630. (Abstract Link)
119. Finnerty JR & TD Gilmore. 2015. Methods for analyzing the evolutionary relationship of NF-κB proteins using free, web-driven bioinformatics and phylogenetic tools. Methods in Molecular Biology 1280: 631-646. (Abstract Link)
120. Yeo AT, S Chennamadhavuni, A Whitty, JA Porco Jr & TD Gilmore. 2015. Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces growth arrest and apoptosis in human B-lymphoma cell lines. Molecules 20: 7474-7494. (Abstract Link)
121. Haery L, RT Thompson & TD Gilmore. 2015. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6: 184-213. (Abstract Link)
122. Alshanbayeva A, A Thomas, M Tremblay, M Abbas, F Abdurrob, T Almojel, A Aparicio, D Asarpota, A Ayers, A Aziz, J Bishop, T Christie, MJM Chua, O Chung, N Dhar, A Diedrich, C Fortin, Q He, S Heerboth, R Hok, A Khedkar, S Kitchloo, C Lawlor, B Leonard, S Linderman, M Maloyan, L Miller, C Pak, A Pandita, I Park, N Patel, J Ramachandran, M Reynoso, Y Samaha, G Thole, J Turnbill, L Xia, J Zhu, C Navarro & TD Gilmore. 2015. N- and C-terminal non-conserved residues contribute to transactivation by a sea anemone (Nematostella vectensis) NF-κB transcription factor. BIOS 86: 165-175. (Abstract Link)
123. Haery L, S Mussakhan, DJ Waxman & TD Gilmore. 2016. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leukemia & Lymphoma 57: 2661-2671. (Abstract Link)
124. Cotter KA, DA Nacci, D Champlin, AT Yeo, TD Gilmore & GV Callard. 2016. Adaptive significance of ERα splice variants in killifish (Fundulus heteroclitus) resident in an estrogenic environment. Endocrinology 157: 2294-2308. (Abstract Link)
125. Mansfield KM, L Nguyen, NM Carter, A Alshanbayeva, LM Williams, C Crowder, AR Penvose, JR Finnerty, VM Weis, TW Siggers & TD Gilmore. 2016. Conserved transcription factor NF-κB is modulated by symbiotic status in a sea anemone model for cnidarian bleaching. Proceedings of the National Academy of Sciences USA, in review. (Abstract Link) (Data Link)
126. Friedman LE, TD Gilmore & JR Finnerty. 2016. Intraspecific variation in peroxide sensitivity in the starlet sea anemone Nematostella vectensis, an estuarine cnidarian. PLoS ONE, in preparation.
127. Cote S, S Chennamadhavuni, A Yeo, U Weber, JA Porco Jr, TD Gilmore & A Whitty. 2016. Use of a fluorescence anisotropy assay to identify inhibitors of the protein-protein interaction between IκB kinase β (IKKβ) and NF-κB essential modulator (NEMO). Manuscript in preparation.
Published Letters to Editor
1. Gilmore TD. 1997. Don’t overlook oncoprotein v-Rel. Journal of NIH Research 9: 14-16.
2. White DW & TD Gilmore. 1997. Transcription factors, oncogenes, and apoptosis. Science (reviewed letter) 276: 185. (Abstract Link)
3. Gilmore TD, DT Starczynowski & D Kalaitzidis. 2004. RELevant gene amplification in B-cell lymphomas? Blood (reviewed letter) 103: 3243. (Abstract Link)
1. Gilmore TD. 2001. Rel. In, Encyclopedia of Molecular Medicine. John Wiley & Sons, New York, NY. Volume 3, pp 2752-2754.
2. Gilmore TD. 2001. Rel. In, Encyclopedic Reference of Cancer (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany. pp 761-764.
3. Gilmore TD. 2004 (updated 2013). Nuclear Factor kappaB. In, Encyclopedia of Biological Chemistry (WJ Lennarz & MD Lane, editors). Elsevier, Oxford, UK. Volume 3, pp 302-305.
4. Gilmore TD & YT Ip. 2009. Signal transduction pathways in development and immunity: NFkB/Rel pathways. (Version 3.0). In, Encyclopedia of Life Sciences, John Wiley & Sons, Ltd. Chichester, UK. http://www.els.net/ [Doi 10.1002/9780470016902.a0002332.pub3]
5. Gilmore TD. 2008. Rel. In, Encyclopedia of Cancer, 2nd Edition (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany.
6. Gilmore TD. 2011. Rel. In, Encyclopedia of Cancer, 3rd Edition (M Schwab, editor). Springer-Verlag Publishers, Heidelberg, Germany.
7. Gilmore TD. 2013. Rel oncogene. In, Brenner’s Online Encyclopedia of Genetics, 2nd Edition (S Malloy, K Hughes, editors). Elsevier, New York. Vol 6, pp 126-128.
8. Gilmore TD, TW Siggers & S Gerondakis. 2016. NF-kappaB and the immune system. In, Encyclopedia of Cell Biology (RA Bradshaw, PD Stahl, eds) Waltham, MA. Volume 3: Functional Cell Biology, pp 580-587.